Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Previous studies have demonstrated that microRNA (miR)-205-5p expression is significantly increased in non‑small cell lung cancer tissues and is associated with tumor differentiation grade. The aim of the present study was to explore the effects of miR‑205‑5p on viability, apoptosis and invasion of lung cancer A549 cells. The hsa‑miR‑205‑5p small interfering RNA (siRNA) inhibitor was transfected into A549 cells and expression of miR‑205‑5p was detected by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR). Cell viability, apoptosis and invasion were assayed by Cell Counting kit‑8, Annexin V/propidium iodide double staining and Transwell assay, respectively. Target genes of miR‑205‑5p were predicted using bioinformatics analysis. Expression of mRNA and protein levels of candidate target genes following miR‑205‑5p inhibition were detected using RT‑qPCR and western blot analysis respectively. The results demonstrated that relative survival rates of A549 cells were significantly inhibited in miR‑205‑5p siRNA‑transfected cells at 24 and 48 h compared with control cells. Apoptosis was markedly increased in the miR‑205‑5p siRNA cells compared with control cells. The number of invaded cells following miR‑205‑5p siRNA silencing was significantly decreased compared with control cells. Bioinformatics analysis revealed that erb‑B2 receptor kinase 3 (erbB3), zinc finger E‑box binding homeobox 2 (ZEB2), clathrin heavy chain (CLTC) and mediator complex subunit 1 (MED1) may be potential target genes of miR‑205‑5p. Reduced expression of miR‑205‑5p significantly increased the expression of ZEB2 mRNA and protein, inhibited the expression of erbB3 protein, but had no significant effect on the expression levels of CLTC and MED1. In summary, reduced expression of miR‑205‑5p promoted apoptosis and inhibited proliferation and invasion in lung cancer A549 cells through upregulation of ZEB2 and downregulation of erbB3. The present results suggested that the increased miR‑205‑5p expression observed in non‑small cell lung cancer tissues may contribute to increased proliferation and invasion of lung cancer cells and thus to cancer progression.

Download full-text PDF

Source
http://dx.doi.org/10.3892/mmr.2017.6398DOI Listing

Publication Analysis

Top Keywords

lung cancer
24
a549 cells
20
expression mir‑205‑5p
16
invasion lung
16
reduced expression
12
mir‑205‑5p
12
proliferation invasion
12
cancer a549
12
cells
12
target genes
12

Similar Publications

Purpose: mutations are classically seen in non-small cell lung cancers (NSCLCs), and EGFR-directed inhibitors have changed the therapeutic landscape in patients with -mutated NSCLC. The real-world prevalence of -mutated ovarian cancers has not been previously described. We aim to determine the prevalence of pathogenic or likely pathogenic mutations in ovarian cancer and describe a case of -mutated metastatic ovarian cancer with a durable response to osimertinib, an EGFR-directed targeted therapy.

View Article and Find Full Text PDF

Reply to: Comments on the Study of Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With -Mutant Lung Cancer.

JCO Precis Oncol

September 2025

Monica F. Chen, MD, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, Daniel Gomez, MD, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, and Helena A. Yu, MD, Division of Solid Tumor Oncology, Depart

View Article and Find Full Text PDF

Objectives: The 9th edition of the Tumor, Node, Metastasis (TNM-9) lung cancer classification is set to replace the 8th edition (TNM-8) starting in 2025. Key updates include the splitting of the mediastinal nodal category N2 into single- and multiple-station involvement, as well as the classification of multiple extrathoracic metastatic lesions as involving a single organ system (M1c1) or multiple organ systems (M1c2). This study aimed to assess how the TNM-9 revisions affect the final staging of lung cancer patients and how these changes correlate with overall survival (OS).

View Article and Find Full Text PDF